Eniporide

本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断

eniporide 是一种 Na(+)/H(+) 交换抑制剂。

eniporide is a Na(+)/H(+) exchange inhibitor. (In Vitro):There is no significant effects of the Na+/H+ exchange inhibitor eniporide on cardiac performance and high energy phosphate content in healthy pig hearts subjected to ischemia/reperfusion induced by crystalloid cardioplegic arrest.(In Vivo):In stage 1, the administration of 100 mg and 150 mg eniporide results in smaller infarct sizes, especially in the angioplasty group. In contrast, in stage 2 there is no difference in the enzymatic infarct size between the three groups. Overall there is no effect of eniporide on clinical outcome (death, cardiogenic shock, heart failure, life-threatening arrhythmias). However, there is a significant reduction of the incidence of heart failure in patients reperfused late (>4 h).

——

Animal Model:Clinically relevant pig models of cardiopulmonary bypass (CPB) and cardioplegia Dosage:3 mg/kg Administration:IV; systemic infusion before cardioplegia with added 2 μM Eniporide or not Result:Had no effect on standard hemodynamics including vascular pressures and cardiac index nor for cardiac performance factors.Reduced myocardial edema and improves heart function.

ENIPORIDE

Endocrinology/Hormones

ATPase

Na+/K+-ATPase

Cardiovascular Disease

——

176644-21-6

320.37

C14H16N4O3S

>98% (HPLC)

DMSO: 10 mM

O=C(/N=C(N)\N)C1=CC(S(=O)(C)=O)=C(N2C=CC=C2)C=C1C

N-(Diaminomethylene)-2-methyl-5-(methylsulfonyl)-4-(1H-pyrrol-1-yl)benzamide

(-20℃)

With Ice Pack

≥ 2 years